ipamorelin e tesamorelin + Blend — GHRH Research Tesamorelin Ipamorelin Research Peptide Blend

Peptide Therapy CJC ipamorelin vs sermorelin compared by mechanism, evidence, dosing, and failure modes

In certain embodiments, pharmaceutical compositions in accordance with the present disclosure may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic or prophylactic effect

Inject both peptides simultaneously for maximum pulse

Because Tesamorelin specifically targets abdominal fat while Ipamorelin supports lean mass maintenance, it provides a unique framework for investigating the reversal of metabolic syndrome

(The 503A Bulks List is a list of drug substances that the FDA has approved for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.) If the peptides meet the safety requirements, the committee will recommend reclassifying them onto this list, so they can then be legally prescribed and compounded